Zeo ScientifiX Files 8-K/A Amendment
Ticker: ZEOX · Form: 8-K/A · Filed: Nov 22, 2024 · CIK: 1557376
Sentiment: neutral
Topics: amendment, disclosure, financials
TL;DR
Zeo ScientifiX filed an amendment to its 8-K, updating financial and disclosure info.
AI Summary
Zeo ScientifiX, Inc. filed an amendment (8-K/A) on November 22, 2024, to its Form 8-K originally reported on November 15, 2024. This amendment pertains to Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Organicell Regenerative Medicine, Inc., is incorporated in Nevada and operates in the Biological Products sector.
Why It Matters
This filing is an amendment to a previous report, indicating updates or corrections to information previously disclosed by Zeo ScientifiX, Inc. regarding financial statements and disclosures.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not introduce new material events or financial distress.
Key Players & Entities
- Zeo ScientifiX, Inc. (company) — Registrant
- November 15, 2024 (date) — Earliest event reported date
- November 22, 2024 (date) — Filing date
- Organicell Regenerative Medicine, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previously filed Form 8-K, specifically addressing Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on November 15, 2024.
What is the filing date of this amendment?
This amendment was filed on November 22, 2024.
What was Zeo ScientifiX, Inc. formerly known as?
Zeo ScientifiX, Inc. was formerly known as Organicell Regenerative Medicine, Inc.
In which state is Zeo ScientifiX, Inc. incorporated?
Zeo ScientifiX, Inc. is incorporated in Nevada.
Filing Stats: 795 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2024-11-22 16:05:25
Filing Documents
- zeoscientifix_8ka.htm (8-K/A) — 32KB
- zeoscientifix_ex99-1.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 232KB
- ex99-1_002.jpg (GRAPHIC) — 616KB
- ex99-1_003.jpg (GRAPHIC) — 390KB
- ex99-1_004.jpg (GRAPHIC) — 380KB
- ex99-1_005.jpg (GRAPHIC) — 217KB
- ex99-1_006.jpg (GRAPHIC) — 445KB
- ex99-1_007.jpg (GRAPHIC) — 515KB
- ex99-1_008.jpg (GRAPHIC) — 558KB
- ex99-1_009.jpg (GRAPHIC) — 439KB
- 0001829126-24-007763.txt ( ) — 5142KB
- ocel-20241115.xsd (EX-101.SCH) — 3KB
- ocel-20241115_lab.xml (EX-101.LAB) — 33KB
- ocel-20241115_pre.xml (EX-101.PRE) — 22KB
- zeoscientifix_8ka_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On November 15, 2024, Robin L. Smith, M.D., M.B.A., a co-founder of Exotropin, LLC (" Exotropin "), will be conducting a presentation entitled " Exosomes are the new Frontier in Aesthetics: Not All Exosomes are Alike " at the Medical Aesthetics Professionals (" MAP ") meeting being held in Scottsdale, Arizona., Exotropin is a privately-held developer of advanced cosmeceuticals using exosomes and other proprietary technology. ZEO holds a minority equity interest in Exotropin and is collaborating with Exotropin on the development of various products, including, ZEO HAIR GROW Powered By Exotropin, which is being introduced at the MAP meeting and which is featured in the presentation. A copy of the PowerPoint slides pertaining to the ZEO HAIR GROW Powered By Exotropin to be used in connection with Dr. Smith's presentation is attached as Exhibit 99.1 to this Report. The foregoing information, including the PowerPoint presentation attached as Exhibit 99.1 to this Report, is being furnished pursuant to Item 7.01 of this Current Report and shall not be deemed " filed " for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended or incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1* November 15, 2024 PowerPoint Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Furnished but not filed. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 22, 2024 ZEO SCIENTIFIX, INC. By: /s/ Ian T. Bothwell Ian T. Bothwell Interim Chief Executive Officer and Chief Financial Officer 2